CRV-431

a non-immunosuppressive analogue of cyclosporine A

Also Known As:

CRV431; N-((7R,8R)-8-((2S,5S,8R,11S,14S,17S,20S,23R,26S,29S,32S)-5-ethyl-11,17,26,29-tetraisobutyl-14,32-diisopropyl-1,7,8,10,16,20,23,25,28,31-decamethyl-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2-yl)-8-H

Networked: 7 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ure, Daren R: 5 articles (01/2024 - 11/2017)
2.	Bobardt, Michael: 4 articles (01/2024 - 11/2019)
3.	Foster, Robert T: 4 articles (01/2024 - 11/2017)
4.	Gallay, Philippe: 4 articles (01/2024 - 11/2019)
5.	Trepanier, Daniel J: 3 articles (11/2019 - 11/2017)
6.	Stauffer, Winston T: 2 articles (01/2024 - 01/2024)
7.	Goodman, Asha Z: 1 article (01/2024)
8.	Huo, Xiang-Yu: 1 article (01/2021)
9.	Lan, Yu: 1 article (01/2021)
10.	Li, Feng-Xia: 1 article (01/2021)

Related Diseases

1.	Liver Diseases (Liver Disease) 11/01/2019 - "In this study, we present findings on the cyclophilin inhibitor, CRV431, that highlight its potential as a drug candidate for chronic liver diseases. " 01/01/2018 - "The developed SMEDDS formulation should allow for effective clinical development of CRV431, targeted to the treatment of liver diseases including hepatitis B (HBV), fibrosis, and hepatocellular carcinoma." 11/01/2019 - "These findings are consistent with CRV431 targeting fibrosis and cancer through multiple, cyclophilin-mediated mechanisms and support the development of CRV431 as a safe and effective drug candidate for liver diseases. " 11/01/2019 - "A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models." 01/01/2020 - "Since we recently demonstrated that both CRV431 and NV556 also inhibit the development of liver fibrosis and hepatocellular carcinoma in nonviral-induced non-alcoholic steatohepatitis mouse models, our present data suggest that the two entirely structurally different CypIs-CRV431 and NV556-derived from unrelated natural products, represent attractive partners to current direct-acting agent (DAA) regimens for the treatment of hepatitis C and liver diseases."
2.	Neoplasms (Cancer) 11/01/2019 - "Additionally, CRV431 administration during a late, oncogenic stage of the NASH disease model resulted in a 50% reduction in the number and size of liver tumors. " 11/01/2019 - "These findings are consistent with CRV431 targeting fibrosis and cancer through multiple, cyclophilin-mediated mechanisms and support the development of CRV431 as a safe and effective drug candidate for liver diseases. " 01/01/2021 - "The non-immune-suppressive cyclophilin inhibitor CRV431 is a clinical candidate to cure nonalcoholic steatohepatitis (NASH) and has the potential to treat liver fibrosis and cancer incidence. " 11/01/2019 - "A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models." 11/01/2019 - "In this study, CRV431 is shown to potently inhibit multiple cyclophilin isoforms, possess several optimized pharmacological properties, and decrease liver fibrosis and tumors in mouse models of chronic liver disease, which highlights its potential to be the first approved drug primarily targeting cyclophilin isomerases."
3.	Fibrosis (Cirrhosis) 01/01/2018 - "The developed SMEDDS formulation should allow for effective clinical development of CRV431, targeted to the treatment of liver diseases including hepatitis B (HBV), fibrosis, and hepatocellular carcinoma." 11/01/2019 - "These findings are consistent with CRV431 targeting fibrosis and cancer through multiple, cyclophilin-mediated mechanisms and support the development of CRV431 as a safe and effective drug candidate for liver diseases. " 11/01/2019 - "A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models."
4.	Liver Cirrhosis (Hepatic Cirrhosis) 11/01/2019 - "Most importantly, CRV431 decreased liver fibrosis in a 6-week carbon tetrachloride model and in a mouse model of nonalcoholic steatohepatitis (NASH). " 01/01/2021 - "The non-immune-suppressive cyclophilin inhibitor CRV431 is a clinical candidate to cure nonalcoholic steatohepatitis (NASH) and has the potential to treat liver fibrosis and cancer incidence. " 01/01/2020 - "Since we recently demonstrated that both CRV431 and NV556 also inhibit the development of liver fibrosis and hepatocellular carcinoma in nonviral-induced non-alcoholic steatohepatitis mouse models, our present data suggest that the two entirely structurally different CypIs-CRV431 and NV556-derived from unrelated natural products, represent attractive partners to current direct-acting agent (DAA) regimens for the treatment of hepatitis C and liver diseases." 11/01/2019 - "In this study, CRV431 is shown to potently inhibit multiple cyclophilin isoforms, possess several optimized pharmacological properties, and decrease liver fibrosis and tumors in mouse models of chronic liver disease, which highlights its potential to be the first approved drug primarily targeting cyclophilin isomerases."
5.	Non-alcoholic Fatty Liver Disease 01/01/2024 - "We previously reported that non-immunosuppressive pan-cyclophilin inhibitor drugs like reconfilstat (CRV431) or NV556 decreased multiple aspects of non-alcoholic fatty liver disease (NAFLD) in mice under two different non-alcoholic steatohepatitis (NASH) mouse models. " 11/01/2019 - "Most importantly, CRV431 decreased liver fibrosis in a 6-week carbon tetrachloride model and in a mouse model of nonalcoholic steatohepatitis (NASH). " 01/01/2021 - "The non-immune-suppressive cyclophilin inhibitor CRV431 is a clinical candidate to cure nonalcoholic steatohepatitis (NASH) and has the potential to treat liver fibrosis and cancer incidence. "

Related Drugs and Biologics

1.	Cyclophilins (Cyclophilin)
2.	Protein Isoforms (Isoforms)
3.	Isomerases
4.	Carbon Tetrachloride (Tetrachloromethane)
5.	Cyclosporine (Ciclosporin)
6.	Antiviral Agents (Antivirals)